Pfizer has agreed to acquire Seagen in a $10 billion deal after a fierce competition with Novo Nordisk to buy the weight-loss drug startup. This acquisition marks a significant move for Pfizer into the innovative drug space and strengthens its position in the pharmaceutical industry. Seagen is known for its pioneering work in obesity and related conditions, making it an attractive asset for major industry players. Analysts note that the demand for weight-loss treatments is steadily increasing, and this deal is expected to solidify Pfizer's presence in this growing market.
